New rules effective March 2026 will allow manufacturers to begin clinical trials with just an intimation, slashing delays and boosting drug innovation and exports.
Regulatory Bottlenecks Eased to Accelerate Drug Development
In a landmark procedural shift, the Indian government has cut the drug trial review period from 90 to 45 working days, aiming to streamline pharmaceutical approvals and spur innovation.
- Effective March 2026, manufacturers can initiate clinical trials or bioequivalence studies by simply submitting a “prior intimation” to the drug regulator.
- Earlier, formal permission via Form CT-10 from the Central Licensing Authority was mandatory—often causing costly delays.
The change follows amendments to the New Drugs and Clinical Trials Rules, now renamed the New Drugs and Clinical Trials (Amendment) Rules, 2026.
Can speed match safety when it comes to human trials?
From Permission to Intimation: A Policy Shift with Teeth
Under the revised rules:
- Companies may begin manufacturing investigational drugs for non-clinical or analytical testing as soon as they receive an acknowledgment of intimation.
- Exceptions include sex hormones, cytotoxic agents, narcotics, and live-biologic drugs, which still require prior approval.
An industry insider noted the new rules eliminate a major pain point in regulatory workflows, calling the earlier 90-day wait a “timeline trap” for small and mid-sized pharma firms.
Will a faster start help India compete in global drug development?
Export Ambitions Get a Push
India, already a major generic drug exporter, is now positioning itself as a faster hub for clinical research and development. Industry voices believe:
- The procedural streamlining will reduce time-to-market for Indian and foreign pharma companies.
- Faster approvals will support exports, especially in bioequivalence testing needed for regulatory filings abroad.
- Firms targeting regulated markets like the US and EU may benefit from shortened local trial cycles.
“This is a smart balancing act between regulatory oversight and business urgency,” said a regulatory affairs consultant familiar with the DTAB discussions.
Could India’s red tape finally be loosening in pharma?
Stakeholder-Driven Reform After Years of Demand
The health ministry initiated the overhaul after inviting public feedback last year. Final amendments were made in consultation with the Drugs Technical Advisory Board (DTAB).
- The updated language formally adds “permission or prior intimation” as a legal basis for trial initiation.
- This offers clarity and legal backing for companies choosing the fast-track route.
Industry insiders anticipate a surge in applications, particularly from firms working on generics, biosimilars, and first-in-class therapies for export.
Will faster drug trials attract global R&D investment to India?
TL;DR
India will allow drug manufacturers to begin clinical trials with just prior intimation, cutting approval time to 45 days from 90. The new rules, effective March 2026, aim to reduce regulatory drag and improve the country’s competitiveness in pharma R&D and exports.
AI Summary
- Review period for clinical trial approvals cut to 45 working days from 90
- Manufacturers can start trials after notifying regulator—no need to wait for approval
- New rules effective March 2026 under amended Drugs and Clinical Trials framework
- Aimed at reducing regulatory delays and promoting exports
- Exceptions apply to specific drug categories (e.g., biologics, narcotics)
